Several factors—such as tumor grade, hormone receptor status, Ki-67 index, tumor size, choice of neoadjuvant regimen, and BRCA mutation status—have been associated with pCR rates [17,18,19,20,21]. The gene discussed is MKI67; the disease is neoplasm.